Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interactions between implantable cardioverter-defibrillators and class III agents

C Movsowitz1, F E Marchlinski

  • 1Department of Medicine, Allegheny University of the Health Sciences, Hahnemann Hospital, Philadelphia, Pennsylvania 19102-1192, USA.

The American Journal of Cardiology
|September 16, 1998
PubMed
Summary

Class III antiarrhythmic drugs are commonly used with implantable cardioverter-defibrillators (ICDs). These drugs can affect ICD effectiveness by altering defibrillation thresholds and ventricular tachycardia cycle length.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of Catheter Ablation of Ventricular Tachycardia in the Setting of Structural Heart Disease.

Current cardiology reports·2016
Same author

Ablation of ventricular tachycardia.

Herzschrittmachertherapie & Elektrophysiologie·2007
Same author

Clinical cardiac electrophysiology fellowship teaching objectives for the new millennium.

Journal of cardiovascular electrophysiology·2002
Same author

Occurrence of implantable defibrillator events in patients with syncope and nonischemic dilated cardiomyopathy.

The American journal of cardiology·2001
Same author

Effects of linear, irrigated-tip radiofrequency ablation in porcine healed anterior infarction.

Journal of cardiovascular electrophysiology·2001
Same author

Changes in local wall thickness correlate with pathologic lesion size following radiofrequency catheter ablation: an intracardiac echocardiographic imaging study.

Echocardiography (Mount Kisco, N.Y.)·2001

Area of Science:

  • Clinical Electrophysiology
  • Cardiology
  • Pharmacology

Background:

  • Implantable cardioverter-defibrillators (ICDs) effectively terminate ventricular arrhythmias.
  • Many ICD patients (40-70%) require antiarrhythmic drugs to prevent recurrent arrhythmias.
  • Class III antiarrhythmic agents are frequently prescribed due to their safety and efficacy.

Purpose of the Study:

  • To evaluate the impact of Class III antiarrhythmic drugs on ICD function.
  • To analyze how these drugs affect defibrillation threshold and ventricular tachycardia cycle length.
  • To assess the proarrhythmic potential of Class III agents in ICD patients.

Main Methods:

  • Review of existing animal and clinical studies on Class III antiarrhythmic drugs and ICDs.

Related Experiment Videos

  • Analysis of drug effects on ventricular refractoriness and defibrillation threshold.
  • Examination of drug-induced changes in ventricular tachycardia cycle length and proarrhythmic events.

    • Main Results:

    • Pure Class III agents decrease defibrillation threshold in canine models.
    • Sotalol consistently decreases defibrillation threshold in animal and clinical studies.
    • Amiodarone shows variable effects on defibrillation threshold in animal models but increases it clinically; it moderately slows ventricular tachycardia cycle length.

    Conclusions:

    • Class III pharmacotherapy can be safely used with ICDs.
    • Understanding drug interactions with ICDs is crucial for effective patient management.
    • Potential proarrhythmic effects, such as torsade de pointes with sotalol or slowed VT below detection rates with amiodarone, must be considered.